| human | Q5 |
| P6178 | Dimensions author ID | 01103103027.63 |
| P856 | official website | https://synapse.mskcc.org/synapse/people/14760 |
| P496 | ORCID iD | 0000-0002-8807-2353 |
| P1153 | Scopus author ID | 56091505700 |
| P108 | employer | Memorial Sloan Kettering Cancer Center | Q1808012 |
| P735 | given name | Eugene | Q545971 |
| Eugene | Q545971 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | male | Q6581097 |
| Q43917433 | Accurate preoperative prediction of non-organ-confined bladder urothelial carcinoma at cystectomy |
| Q53092088 | Association of oncofetal protein expression with clinical outcomes in patients with urothelial carcinoma of the bladder. |
| Q37987066 | Biomolecular predictors of urothelial cancer behavior and treatment outcomes |
| Q38321861 | Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer |
| Q44505483 | Chronological age is not an independent predictor of clinical outcomes after radical nephroureterectomy |
| Q113752510 | Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype |
| Q82235496 | Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment |
| Q91655062 | Comparison of Postradical Cystectomy Ileus Rates Using GIA-80 Versus GIA-60 Intestinal Stapler Device |
| Q50491049 | Cost-effective treatment of low-risk carcinoma not invading bladder muscle. |
| Q27005948 | Current status of robotic partial nephrectomy (RPN) |
| Q38764205 | DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma |
| Q83192683 | Death certificates are valid for the determination of cause of death in patients with upper and lower tract urothelial carcinoma |
| Q84787916 | Decision curve analysis assessing the clinical benefit of NMP22 in the detection of bladder cancer: secondary analysis of a prospective trial |
| Q45843908 | Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinoma |
| Q59649530 | Extranodal Extension Is a Powerful Prognostic Factor in Bladder Cancer Patients with Lymph Node Metastasis |
| Q38792051 | Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. |
| Q36913690 | Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma |
| Q36362571 | Genomic Characterization of Upper Tract Urothelial Carcinoma |
| Q44338887 | Genomic characterization of response to chemoradiation in urothelial bladder cancer |
| Q35034441 | Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder |
| Q38154012 | High rates of advanced disease, complications, and decline of renal function after radical nephroureterectomy. |
| Q36773321 | Immunocytology is a strong predictor of bladder cancer presence in patients with painless hematuria: a multicentre study. |
| Q37902697 | Immunohistochemical biomarkers for bladder cancer prognosis |
| Q57165116 | Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma |
| Q37886832 | Impact of gender on bladder cancer incidence, staging, and prognosis |
| Q45049759 | Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma |
| Q37672873 | Impact of smoking on oncologic outcomes of upper tract urothelial carcinoma after radical nephroureterectomy. |
| Q40060285 | Incidence and Effect of Thromboembolic Events in Radical Cystectomy Patients Undergoing Preoperative Chemotherapy for Muscle-invasive Bladder Cancer |
| Q28511160 | Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance |
| Q53135154 | International validation of the prognostic value of subclassification for AJCC stage pT3 upper tract urothelial carcinoma of the renal pelvis. |
| Q45202138 | Loss of SPINK1 expression is associated with unfavorable outcomes in urothelial carcinoma of the bladder after radical cystectomy |
| Q82082555 | Multicenter validation of the prognostic value of patient age in patients treated with radical cystectomy |
| Q39352697 | Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets |
| Q86515833 | Nonneoplastic renal cortical scarring at tumor nephrectomy predicts decline in kidney function |
| Q37950459 | Novel therapeutics for the management of castration-resistant prostate cancer (CRPC). |
| Q44519064 | Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy |
| Q50493416 | Outcomes and prognostic factors in patients with a single lymph node metastasis at time of radical cystectomy. |
| Q44648038 | Pathologic nodal staging score for bladder cancer: a decision tool for adjuvant therapy after radical cystectomy |
| Q52597038 | Poor prognosis of bladder cancer patients with occult lymph node metastases treated with neoadjuvant chemotherapy. |
| Q53136632 | Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. |
| Q46489162 | Predictors of cancer-specific mortality after disease recurrence following radical cystectomy |
| Q45657847 | Preoperative radiographic parameters predict long-term renal impairment following partial nephrectomy |
| Q26772220 | Prognostic Genetic Signatures in Upper Tract Urothelial Carcinoma |
| Q40085142 | Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma |
| Q45733362 | Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients |
| Q37897483 | Prognostic factors for upper urinary tract urothelial carcinoma |
| Q44037317 | Prognostic value of extranodal extension and other lymph node parameters in patients with upper tract urothelial carcinoma |
| Q38407148 | Prognostic value of insulin-like growth factor II mRNA binding protein 3 in patients treated with radical prostatectomy |
| Q28084159 | Radical transurethral resection alone, robotic or partial cystectomy, or extended lymphadenectomy: can we select patients with muscle invasion for less or more surgery? |
| Q26772222 | Rationale and Early Experience with Prophylactic Placement of Mesh to Prevent Parastomal Hernia Formation after Ileal Conduit Urinary Diversion and Cystectomy for Bladder Cancer |
| Q86904390 | Re: whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation |
| Q37822392 | Recent advances in robot-assisted radical cystectomy |
| Q34143388 | Risk factors for the development of parastomal hernia after radical cystectomy. |
| Q36623107 | Risk of cancer-specific mortality following recurrence after radical nephroureterectomy |
| Q83001143 | Risk stratification of organ confined bladder cancer after radical cystectomy using cell cycle related biomarkers |
| Q38002448 | Role of magnetic resonance imaging in bladder cancer: current status and emerging techniques |
| Q64998827 | Stage pT0 after radical cystectomy: are all patients equal? |
| Q50502175 | Stage-specific impact of tumor location on oncologic outcomes in patients with upper and lower tract urothelial carcinoma following radical surgery. |
| Q37053820 | Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer |
| Q85047199 | The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy |
| Q83322195 | The use of 5α-reductase inhibitors for the prevention and treatment of prostate cancer |
| Q33220331 | Tim-2 regulates T helper type 2 responses and autoimmunity |
Search more.